Q4 2025 EyePoint Inc Earnings Call Transcript
Key Points
- EyePoint Inc (EYPT) has made significant progress in 2025, advancing its lead asset, DURAVYU, in clinical trials for wet AMD and DME.
- DURAVYU has shown a compelling clinical profile with durable efficacy, improved vision, and a favorable safety profile in over 190 patients across four completed clinical trials.
- The company has a strong cash position of $306 million, expected to fund operations into the fourth quarter of 2027.
- EyePoint Inc (EYPT) is preparing for a potential US launch of DURAVYU, with a seasoned commercial leader, Michael Campbell, joining as Chief Commercial Officer.
- The company is expanding operations at its CGMP manufacturing facility, supporting both NDA submission and commercial supply readiness.
- Total net revenue for the quarter ended December 31, 2025, was significantly lower at $0.6 million compared to $11.6 million for the same period in 2024.
- Operating expenses increased to $71 million for the quarter ended December 31, 2025, primarily due to ongoing Phase III trials.
- Net loss for the quarter was approximately $68 million, a significant increase from the $41 million net loss in the prior year period.
- The decrease in total net revenue for the full year 2025 was primarily driven by the recognition of remaining deferred revenue related to the company's agreement for the license of YUTIQ product rights.
- Despite the progress, there are still uncertainties regarding regulatory approvals and the competitive landscape in the retinal disease market.
Morning. My name is Michelle, and I'll be your conference operator and recent corporate development conference call. There will be a question-and-answer session to flow at the completion of the prepared remarks. Please be advised that today's conference is being recorded at the company's request. I would now like to turn the call over to Greg Elston, Executive Vice President and Chief Financial Officer of EyePoint. Sir. Please go ahead.
Thank you, and thank you all for joining us on today's conference call to discuss EyePoint's Fourth Quarter and Full Year 2025 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer of EyePoint. Jay will begin with a review of recent corporate updates and discuss our clinical programs for DuraView and wet AMD and DME. I will close with commentary on the fourth quarter and full year 2025 financial results. . We will then open the call for your questions where we will be joined by Dr. Ramiro Robero, our Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
